Shionogi takes InterMune to US court, claiming unpaid EU royalties for Esbriet
This article was originally published in Scrip
Executive Summary
Shionogi has lodged a legal action in the US against InterMune, claiming that the US firm has failed to pay due royalties on sales of the idiopathic pulmonary fibrosis (IPF) drug Esbriet (pirfenidone) in the EU.